You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMethoxyflurane
Accession NumberDB01028  (APRD00744)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionAn inhalation anesthetic. Currently, methoxyflurane is rarely used for surgical, obstetric, or dental anesthesia. If so employed, it should be administered with nitrous oxide to achieve a relatively light level of anesthesia, and a neuromuscular blocking agent given concurrently to obtain the desired degree of muscular relaxation. (From AMA Drug Evaluations Annual, 1994, p180)
Structure
Thumb
Synonyms
Methoflurane
Methoxyfluoran
Methoxyfluran
Methoxyfluranum
Methyl 1,1-difluoro-2,2-dichloroethyl ether
Metoxiflurano
Penthrane
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
PenthraneAbbott Laboratories
Brand mixturesNot Available
SaltsNot Available
Categories
UNII30905R8O7B
CAS number76-38-0
WeightAverage: 164.966
Monoisotopic: 163.960726574
Chemical FormulaC3H4Cl2F2O
InChI KeyRFKMCNOHBTXSMU-UHFFFAOYSA-N
InChI
InChI=1S/C3H4Cl2F2O/c1-8-3(6,7)2(4)5/h2H,1H3
IUPAC Name
2,2-dichloro-1,1-difluoro-1-methoxyethane
SMILES
COC(F)(F)C(Cl)Cl
Pharmacology
IndicationFor use in the induction and maintenance of general anesthesia
Structured Indications Not Available
PharmacodynamicsMethoxyflurane is a general inhalation anesthetic used for induction and maintenance of general anesthesia. It induces muscle relaxation and reduces pains sensitivity by altering tissue excitability. It does so by decreasing the extent of gap junction mediated cell-cell coupling and altering the activity of the channels that underlie the action potential.
Mechanism of actionMethoxyflurane induces a reduction in junctional conductance by decreasing gap junction channel opening times and increasing gap junction channel closing times. Methoxyflurane also activates calcium dependent ATPase in the sarcoplasmic reticulum by increasing the fluidity of the lipid membrane. It also appears to bind the D subunit of ATP synthase and NADH dehydogenase. Methoxyflurane also binds to the GABA receptor, the large conductance Ca2+ activated potassium channel, the glutamate receptor and the glycine receptor.
TargetKindPharmacological actionActionsOrganismUniProt ID
Gamma-aminobutyric acid receptor subunit alpha-1Proteinyes
agonist
HumanP14867 details
Glutamate receptor 1Proteinyes
antagonist
HumanP42261 details
Glycine receptor subunit alpha-1Proteinyes
agonist
HumanP23415 details
Calcium-transporting ATPase type 2C member 1Proteinunknown
inhibitor
HumanP98194 details
Potassium voltage-gated channel subfamily A member 1Proteinyes
inducer
HumanQ09470 details
ATP synthase subunit delta, mitochondrialProteinunknown
unknown
HumanP30049 details
NADH-ubiquinone oxidoreductase chain 1Proteinunknown
unknown
HumanP03886 details
GABA-A receptor (anion channel)Protein groupyes
positive allosteric modulator
Humannot applicabledetails
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic.

Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityLD50=3600 mg/kg (Orally in rats). Symptoms of overexposure include eye irritation, CNS depression, analgesia, anesthesia, seizures, respiratory depression, and liver and kidney damage.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with 1,1,1,2 Tetrafluoroethane.Investigational
7-NitroindazoleThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with 7-Nitroindazole.Experimental
AbirateroneThe serum concentration of Methoxyflurane can be increased when it is combined with Abiraterone.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Aceprometazine.Approved
adipiplonThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Agomelatine.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Methoxyflurane.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Methoxyflurane.Approved, Illicit, Investigational
AmiodaroneThe metabolism of Methoxyflurane can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Amperozide.Experimental
AprepitantThe serum concentration of Methoxyflurane can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Aripiprazole.Approved, Investigational
ArtemetherThe metabolism of Methoxyflurane can be decreased when combined with Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Asenapine.Approved
AtazanavirThe metabolism of Methoxyflurane can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Methoxyflurane can be decreased when combined with Atomoxetine.Approved
Atracurium besylateMethoxyflurane may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Azaperone.Vet Approved
AzelastineMethoxyflurane may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Azelastine.Approved
AzithromycinThe metabolism of Methoxyflurane can be decreased when combined with Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Barbital.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Benzocaine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Benzyl alcohol.Approved
BetaxololThe metabolism of Methoxyflurane can be decreased when combined with Betaxolol.Approved
BexaroteneThe serum concentration of Methoxyflurane can be decreased when it is combined with Bexarotene.Approved, Investigational
BoceprevirThe metabolism of Methoxyflurane can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Methoxyflurane can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Methoxyflurane can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Methoxyflurane.Approved
BromazepamThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Bromazepam.Approved, Illicit
BrompheniramineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Brotizolam.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Methoxyflurane.Approved, Investigational
BuprenorphineMethoxyflurane may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Methoxyflurane can be decreased when combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Methoxyflurane.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Methoxyflurane.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Methoxyflurane.Approved, Illicit, Vet Approved
CaffeineThe metabolism of Methoxyflurane can be decreased when combined with Caffeine.Approved
CapecitabineThe metabolism of Methoxyflurane can be decreased when combined with Capecitabine.Approved, Investigational
CarbamazepineThe metabolism of Methoxyflurane can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Carisoprodol.Approved
CelecoxibThe metabolism of Methoxyflurane can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Methoxyflurane can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Methoxyflurane.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Chloroprocaine.Approved
ChloroquineThe metabolism of Methoxyflurane can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Chlorphenamine.Approved
ChlorpromazineThe metabolism of Methoxyflurane can be decreased when combined with Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Methoxyflurane can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CimetidineThe metabolism of Methoxyflurane can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Methoxyflurane can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Methoxyflurane.Approved, Vet Approved
CitalopramThe metabolism of Methoxyflurane can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Methoxyflurane can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Methoxyflurane can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Clidinium.Approved
ClobazamThe metabolism of Methoxyflurane can be decreased when combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with clomethiazole.Investigational
ClomipramineThe metabolism of Methoxyflurane can be decreased when combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Clonidine.Approved
ClopidogrelThe metabolism of Methoxyflurane can be decreased when combined with Clopidogrel.Approved, Nutraceutical
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Methoxyflurane.Approved, Illicit
ClotrimazoleThe metabolism of Methoxyflurane can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Methoxyflurane can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Methoxyflurane can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Methoxyflurane can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Methoxyflurane.Approved, Illicit
ConivaptanThe serum concentration of Methoxyflurane can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Methoxyflurane can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Methoxyflurane.Approved
CyclosporineThe metabolism of Methoxyflurane can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Cyproheptadine.Approved
Cyproterone acetateThe serum concentration of Methoxyflurane can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Methoxyflurane can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Methoxyflurane.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Dapoxetine.Investigational
DarifenacinThe metabolism of Methoxyflurane can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Methoxyflurane can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Methoxyflurane can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Methoxyflurane can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Methoxyflurane can be decreased when combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Desflurane.Approved
DesipramineThe metabolism of Methoxyflurane can be decreased when combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Methoxyflurane can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Methoxyflurane.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Methoxyflurane.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Methoxyflurane.Approved, Illicit, Vet Approved
DifenoxinThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe metabolism of Methoxyflurane can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Methoxyflurane can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Dimenhydrinate.Approved
DiphenhydramineThe metabolism of Methoxyflurane can be decreased when combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Diphenoxylate.Approved, Illicit
DisulfiramThe metabolism of Methoxyflurane can be decreased when combined with Disulfiram.Approved
DopamineMethoxyflurane may increase the arrhythmogenic activities of Dopamine.Approved
DoramectinThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Doxepin.Approved
DoxorubicinThe metabolism of Methoxyflurane can be decreased when combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Methoxyflurane can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Methoxyflurane.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Methoxyflurane.Approved, Illicit
DronedaroneThe metabolism of Methoxyflurane can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Methoxyflurane.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Drotebanol.Experimental, Illicit
DuloxetineThe metabolism of Methoxyflurane can be decreased when combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Methoxyflurane.Approved
EcgonineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Ecopipam.Investigational
EfavirenzThe serum concentration of Methoxyflurane can be decreased when it is combined with Efavirenz.Approved, Investigational
EliglustatThe metabolism of Methoxyflurane can be decreased when combined with Eliglustat.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Methoxyflurane.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Methoxyflurane can be decreased when it is combined with Enzalutamide.Approved
EphedraEphedra may increase the arrhythmogenic activities of Methoxyflurane.Approved, Nutraceutical, Withdrawn
EphedrineEphedrine may increase the arrhythmogenic activities of Methoxyflurane.Approved
EpinephrineMethoxyflurane may increase the arrhythmogenic activities of Epinephrine.Approved, Vet Approved
ErythromycinThe metabolism of Methoxyflurane can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Methoxyflurane can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstazolamThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Methoxyflurane.Approved
EthanolMethoxyflurane may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methoxyflurane.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Methoxyflurane.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Methoxyflurane can be decreased when it is combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Methoxyflurane.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Flibanserin.Approved
FloxuridineThe metabolism of Methoxyflurane can be decreased when combined with Floxuridine.Approved
FluconazoleThe metabolism of Methoxyflurane can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Flunitrazepam.Approved, Illicit
FluorouracilThe metabolism of Methoxyflurane can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Methoxyflurane can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Methoxyflurane.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Methoxyflurane.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Methoxyflurane.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Fluticasone Propionate.Approved
FluvastatinThe metabolism of Methoxyflurane can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Methoxyflurane can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolMethoxyflurane may increase the arrhythmogenic activities of Formoterol.Approved, Investigational
FosamprenavirThe metabolism of Methoxyflurane can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Methoxyflurane can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Methoxyflurane can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Fospropofol.Approved, Illicit
Fusidic AcidThe serum concentration of Methoxyflurane can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Methoxyflurane.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with gabapentin enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GemfibrozilThe metabolism of Methoxyflurane can be decreased when combined with Gemfibrozil.Approved
GepironeThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Glutethimide.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Methoxyflurane.Approved, Illicit, Withdrawn
HaloperidolThe metabolism of Methoxyflurane can be decreased when combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Heroin.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Hexobarbital.Approved
HydrocodoneMethoxyflurane may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Methoxyflurane.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Methoxyflurane.Approved
IdelalisibThe serum concentration of Methoxyflurane can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Iloperidone.Approved
ImatinibThe metabolism of Methoxyflurane can be decreased when combined with Imatinib.Approved
ImipramineThe metabolism of Methoxyflurane can be decreased when combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Methoxyflurane can be decreased when combined with Indinavir.Approved
IrbesartanThe metabolism of Methoxyflurane can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Methoxyflurane can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Methoxyflurane.Approved, Vet Approved
IsoniazidThe metabolism of Methoxyflurane can be decreased when combined with Isoniazid.Approved
IsoprenalineMethoxyflurane may increase the arrhythmogenic activities of Isoprenaline.Approved
IsradipineThe metabolism of Methoxyflurane can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Methoxyflurane can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Methoxyflurane can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Ketobemidone.Approved
KetoconazoleThe metabolism of Methoxyflurane can be decreased when combined with Ketoconazole.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Lamotrigine.Approved, Investigational
LeflunomideThe metabolism of Methoxyflurane can be decreased when combined with Leflunomide.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Methoxyflurane.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Methoxyflurane.Approved
LidocaineThe metabolism of Methoxyflurane can be decreased when combined with Lidocaine.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Lofentanil.Illicit
LopinavirThe metabolism of Methoxyflurane can be decreased when combined with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Methoxyflurane.Approved
LorcaserinThe metabolism of Methoxyflurane can be decreased when combined with Lorcaserin.Approved
LosartanThe metabolism of Methoxyflurane can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Methoxyflurane can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Methoxyflurane.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Methoxyflurane is combined with Lu AA21004.Investigational
LuliconazoleThe serum concentration of Methoxyflurane can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Methoxyflurane can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Methoxyflurane can be decreased when combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Methoxyflurane.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Maprotiline.Approved
MeclizineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Melperone.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Methoxyflurane.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Methoxyflurane.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Methoxyflurane.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Metaxalone.Approved
MethadoneThe metabolism of Methoxyflurane can be decreased when combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Methoxyflurane.Approved
MethotrimeprazineMethoxyflurane may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethsuximideThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Methsuximide.Approved
MethylphenidateMethylphenidate may increase the hypertensive activities of Methoxyflurane.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Methoxyflurane.Approved
MetoprololThe metabolism of Methoxyflurane can be decreased when combined with Metoprolol.Approved, Investigational
MetyrosineMethoxyflurane may increase the sedative activities of Metyrosine.Approved
MexiletineThe metabolism of Methoxyflurane can be decreased when combined with Mexiletine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Methoxyflurane.Approved, Illicit
MifepristoneThe serum concentration of Methoxyflurane can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Methoxyflurane.Approved, Investigational
MirabegronThe metabolism of Methoxyflurane can be decreased when combined with Mirabegron.Approved
MirtazapineMethoxyflurane may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Methoxyflurane can be decreased when it is combined with Mitotane.Approved
MivacuriumMethoxyflurane may increase the neuromuscular blocking activities of Mivacurium.Approved
ModafinilThe serum concentration of Methoxyflurane can be decreased when it is combined with Modafinil.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Methoxyflurane.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Methoxyflurane.Approved, Investigational
NafcillinThe serum concentration of Methoxyflurane can be decreased when it is combined with Nafcillin.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Methoxyflurane.Approved
NefazodoneThe metabolism of Methoxyflurane can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Methoxyflurane can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Methoxyflurane can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Methoxyflurane can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Methoxyflurane can be decreased when combined with Nicardipine.Approved
NicotineThe metabolism of Methoxyflurane can be decreased when combined with Nicotine.Approved
NilotinibThe metabolism of Methoxyflurane can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Nitrous oxide.Approved, Vet Approved
NorepinephrineMethoxyflurane may increase the arrhythmogenic activities of Norepinephrine.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Methoxyflurane.Approved, Investigational
OlaparibThe metabolism of Methoxyflurane can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Olopatadine.Approved
OmeprazoleThe metabolism of Methoxyflurane can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Methoxyflurane.Approved
OpiumThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Opium.Approved, Illicit
OrphenadrineMethoxyflurane may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Methoxyflurane can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Methoxyflurane.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Methoxyflurane.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Methoxyflurane.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Oxymorphone.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Methoxyflurane can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Paliperidone.Approved
PanobinostatThe serum concentration of Methoxyflurane can be increased when it is combined with Panobinostat.Approved, Investigational
ParaldehydeMethoxyflurane may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe metabolism of Methoxyflurane can be decreased when combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Methoxyflurane can be decreased when it is combined with Peginterferon alfa-2b.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Methoxyflurane.Approved, Vet Approved
PentobarbitalThe metabolism of Methoxyflurane can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Methoxyflurane.Approved
PerazineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Methoxyflurane.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Methoxyflurane.Approved
PhenobarbitalThe metabolism of Methoxyflurane can be increased when combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Phenoxyethanol.Approved
PhenytoinThe metabolism of Methoxyflurane can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Pimozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Methoxyflurane can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleMethoxyflurane may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Methoxyflurane.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Methoxyflurane.Approved
PrimidoneThe metabolism of Methoxyflurane can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Methoxyflurane.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methoxyflurane.Approved, Vet Approved
PromazineThe metabolism of Methoxyflurane can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Promethazine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Methoxyflurane.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Methoxyflurane.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Protriptyline.Approved
PSD502The risk or severity of adverse effects can be increased when Methoxyflurane is combined with PSD502.Investigational
PyrimethamineThe metabolism of Methoxyflurane can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe serum concentration of Methoxyflurane can be increased when it is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Quetiapine.Approved
QuinidineThe metabolism of Methoxyflurane can be decreased when combined with Quinidine.Approved
QuinineThe metabolism of Methoxyflurane can be decreased when combined with Quinine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Ramelteon.Approved, Investigational
RanolazineThe metabolism of Methoxyflurane can be decreased when combined with Ranolazine.Approved, Investigational
RapacuroniumMethoxyflurane may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Methoxyflurane.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Methoxyflurane.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Methoxyflurane.Approved
RifabutinThe metabolism of Methoxyflurane can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Methoxyflurane can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Methoxyflurane can be increased when combined with Rifapentine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Methoxyflurane.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Ritanserin.Investigational
RitonavirThe metabolism of Methoxyflurane can be decreased when combined with Ritonavir.Approved, Investigational
RolapitantThe metabolism of Methoxyflurane can be decreased when combined with Rolapitant.Approved
RomifidineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Romifidine.Vet Approved
RopiniroleMethoxyflurane may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Methoxyflurane.Approved
RotigotineMethoxyflurane may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Methoxyflurane.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with S-Ethylisothiourea.Experimental
Sage 547The risk or severity of adverse effects can be increased when Methoxyflurane is combined with Sage 547.Investigational
SaquinavirThe metabolism of Methoxyflurane can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Scopolamine.Approved
SecobarbitalThe metabolism of Methoxyflurane can be increased when combined with Secobarbital.Approved, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Sertindole.Approved, Withdrawn
SertralineThe metabolism of Methoxyflurane can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe metabolism of Methoxyflurane can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Methoxyflurane can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Methoxyflurane can be increased when it is combined with Simeprevir.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Methoxyflurane.Approved
SorafenibThe metabolism of Methoxyflurane can be decreased when combined with Sorafenib.Approved, Investigational
St. John's WortThe serum concentration of Methoxyflurane can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Methoxyflurane can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Methoxyflurane.Approved, Investigational
SulfadiazineThe metabolism of Methoxyflurane can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Methoxyflurane can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Methoxyflurane can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Methoxyflurane.Approved
SuvorexantMethoxyflurane may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Methoxyflurane.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Tasimelteon.Approved
TelaprevirThe metabolism of Methoxyflurane can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Methoxyflurane can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Methoxyflurane.Approved
TenofovirThe metabolism of Methoxyflurane can be decreased when combined with Tenofovir.Approved, Investigational
TerbinafineThe metabolism of Methoxyflurane can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TeriflunomideThe serum concentration of Methoxyflurane can be decreased when it is combined with Teriflunomide.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Tetrodotoxin.Investigational
ThalidomideMethoxyflurane may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Methoxyflurane can be decreased when combined with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Methoxyflurane.Approved, Vet Approved
ThioridazineThe metabolism of Methoxyflurane can be decreased when combined with Thioridazine.Approved
ThiotepaThe metabolism of Methoxyflurane can be decreased when combined with Thiotepa.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Tiapride.Investigational
TicagrelorThe metabolism of Methoxyflurane can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Methoxyflurane can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Tiletamine.Vet Approved
TipranavirThe metabolism of Methoxyflurane can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Methoxyflurane can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Methoxyflurane can be decreased when combined with Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Methoxyflurane.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe metabolism of Methoxyflurane can be decreased when combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Methoxyflurane.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Methoxyflurane.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Methoxyflurane.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Methoxyflurane.Approved, Vet Approved
TrimethoprimThe metabolism of Methoxyflurane can be decreased when combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Triprolidine.Approved
Uc1010The risk or severity of adverse effects can be increased when Methoxyflurane is combined with Uc1010.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Methoxyflurane.Approved, Investigational
ValsartanThe metabolism of Methoxyflurane can be decreased when combined with Valsartan.Approved, Investigational
VemurafenibThe serum concentration of Methoxyflurane can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Methoxyflurane can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Methoxyflurane can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Vigabatrin.Approved
VoriconazoleThe metabolism of Methoxyflurane can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Xylazine.Vet Approved
ZafirlukastThe metabolism of Methoxyflurane can be decreased when combined with Zafirlukast.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Methoxyflurane.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Methoxyflurane can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Zolazepam.Vet Approved
ZolpidemMethoxyflurane may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Zuclopenthixol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesN02BG09
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (52.9 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9921
Caco-2 permeable+0.6119
P-glycoprotein substrateNon-substrate0.8535
P-glycoprotein inhibitor INon-inhibitor0.9588
P-glycoprotein inhibitor IINon-inhibitor0.9203
Renal organic cation transporterNon-inhibitor0.9227
CYP450 2C9 substrateNon-substrate0.7959
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.6542
CYP450 1A2 substrateNon-inhibitor0.6508
CYP450 2C9 inhibitorNon-inhibitor0.8587
CYP450 2D6 inhibitorNon-inhibitor0.9407
CYP450 2C19 inhibitorNon-inhibitor0.6081
CYP450 3A4 inhibitorNon-inhibitor0.9753
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8956
Ames testNon AMES toxic0.9132
CarcinogenicityCarcinogens 0.7261
BiodegradationNot ready biodegradable0.9737
Rat acute toxicity1.6296 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9515
hERG inhibition (predictor II)Non-inhibitor0.9016
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateLiquid
Experimental Properties
PropertyValueSource
melting point-35 °CPhysProp
boiling point105 °CPhysProp
water solubility2.83E+004 mg/L (at 37 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP2.21HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility6.46 mg/mLALOGPS
logP2.01ALOGPS
logP2.31ChemAxon
logS-1.4ALOGPS
pKa (Strongest Basic)-4.5ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area9.23 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity27.97 m3·mol-1ChemAxon
Polarizability11.46 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (7.12 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-001i-9100000000-e9387eb71a01da84865eView in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dialkyl ethers. These are organic compounds containing the dialkyl ether functional group, with the formula ROR', where R and R' are alkyl groups.
KingdomOrganic compounds
Super ClassOrganooxygen compounds
ClassEthers
Sub ClassDialkyl ethers
Direct ParentDialkyl ethers
Alternative Parents
Substituents
  • Dialkyl ether
  • Hydrocarbon derivative
  • Organofluoride
  • Organochloride
  • Organohalogen compound
  • Alkyl halide
  • Alkyl fluoride
  • Alkyl chloride
  • Aliphatic acyclic compound
Molecular FrameworkAliphatic acyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRA1
Uniprot ID:
P14867
Molecular Weight:
51801.395 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Moody EJ, Suzdak PD, Paul SM, Skolnick P: Modulation of the benzodiazepine/gamma-aminobutyric acid receptor chloride channel complex by inhalation anesthetics. J Neurochem. 1988 Nov;51(5):1386-93. [PubMed:2459308 ]
  4. Moody EJ, Skolnick P: The imidazobenzodiazepine Ro 15-4513 antagonizes methoxyflurane anesthesia. Life Sci. 1988;43(16):1269-76. [PubMed:2845216 ]
  5. Krasowski MD, Harrison NL: The actions of ether, alcohol and alkane general anaesthetics on GABAA and glycine receptors and the effects of TM2 and TM3 mutations. Br J Pharmacol. 2000 Feb;129(4):731-43. [PubMed:10683198 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Pdz domain binding
Specific Function:
Ionotropic glutamate receptor. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and thereby converts the chemical signal to an electrical impulse. The receptor then desensitizes rapidly and enters a transient inacti...
Gene Name:
GRIA1
Uniprot ID:
P42261
Molecular Weight:
101505.245 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Martin DC, Plagenhoef M, Abraham J, Dennison RL, Aronstam RS: Volatile anesthetics and glutamate activation of N-methyl-D-aspartate receptors. Biochem Pharmacol. 1995 Mar 15;49(6):809-17. [PubMed:7702639 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Transmitter-gated ion channel activity
Specific Function:
The glycine receptor is a neurotransmitter-gated ion channel. Binding of glycine to its receptor increases the chloride conductance and thus produces hyperpolarization (inhibition of neuronal firing).
Gene Name:
GLRA1
Uniprot ID:
P23415
Molecular Weight:
52623.35 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Krasowski MD, Harrison NL: The actions of ether, alcohol and alkane general anaesthetics on GABAA and glycine receptors and the effects of TM2 and TM3 mutations. Br J Pharmacol. 2000 Feb;129(4):731-43. [PubMed:10683198 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Signal transducer activity
Specific Function:
This magnesium-dependent enzyme catalyzes the hydrolysis of ATP coupled with the transport of the calcium.
Gene Name:
ATP2C1
Uniprot ID:
P98194
Molecular Weight:
100576.42 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Lopez MM, Kosk-Kosicka D: How do volatile anesthetics inhibit Ca(2+)-ATPases? J Biol Chem. 1995 Nov 24;270(47):28239-45. [PubMed:7499320 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inducer
General Function:
Voltage-gated potassium channel activity
Specific Function:
Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain and the central nervous system, but also in the kidney (PubMed:19903818). Contributes to the regulation of the membrane potential and nerve signaling, and prevents neuronal hyperexcitability (PubMed:17156368). Forms tetrameric potassium-selective channels through which ...
Gene Name:
KCNA1
Uniprot ID:
Q09470
Molecular Weight:
56465.01 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Elliott JR, Elliott AA, Harper AA, Winpenny JP: Effects of general anaesthetics on neuronal sodium and potassium channels. Gen Pharmacol. 1992 Nov;23(6):1005-11. [PubMed:1336744 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
unknown
General Function:
Transporter activity
Specific Function:
Mitochondrial membrane ATP synthase (F(1)F(0) ATP synthase or Complex V) produces ATP from ADP in the presence of a proton gradient across the membrane which is generated by electron transport complexes of the respiratory chain. F-type ATPases consist of two structural domains, F(1) - containing the extramembraneous catalytic core, and F(0) - containing the membrane proton channel, linked toget...
Gene Name:
ATP5D
Uniprot ID:
P30049
Molecular Weight:
17489.755 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
unknown
General Function:
Nadh dehydrogenase (ubiquinone) activity
Specific Function:
Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) that is believed to belong to the minimal assembly required for catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone (By similarity).
Gene Name:
MT-ND1
Uniprot ID:
P03886
Molecular Weight:
35660.055 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein group
Organism
Human
Pharmacological action
yes
Actions
positive allosteric modulator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By similarity).
Components:
NameUniProt IDDetails
Gamma-aminobutyric acid receptor subunit alpha-1P14867 Details
Gamma-aminobutyric acid receptor subunit alpha-2P47869 Details
Gamma-aminobutyric acid receptor subunit alpha-3P34903 Details
Gamma-aminobutyric acid receptor subunit alpha-4P48169 Details
Gamma-aminobutyric acid receptor subunit alpha-5P31644 Details
Gamma-aminobutyric acid receptor subunit alpha-6Q16445 Details
Gamma-aminobutyric acid receptor subunit beta-1P18505 Details
Gamma-aminobutyric acid receptor subunit beta-2P47870 Details
Gamma-aminobutyric acid receptor subunit beta-3P28472 Details
Gamma-aminobutyric acid receptor subunit deltaO14764 Details
Gamma-aminobutyric acid receptor subunit epsilonP78334 Details
Gamma-aminobutyric acid receptor subunit gamma-1Q8N1C3 Details
Gamma-aminobutyric acid receptor subunit gamma-2P18507 Details
Gamma-aminobutyric acid receptor subunit gamma-3Q99928 Details
Gamma-aminobutyric acid receptor subunit piO00591 Details
Gamma-aminobutyric acid receptor subunit thetaQ9UN88 Details
References
  1. ChEMBL Compound Report Card [Link]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23